Samsung Biologics Signs Record-Breaking 2 Trillion Won Contract

Mega CMO Contract Worth $1.41 Billion Signed with European Firm Until 2030
Accounts for 40% of Last Year's Total Orders... Cumulative Orders Surpass $17.6 Billion

Samsung Biologics has signed its largest-ever contract worth 2 trillion KRW. This amount accounts for 40% of last year's total orders of 5.4035 trillion KRW. Despite challenging business conditions for domestic companies, such as a sharp rise in exchange rates due to increased political uncertainty following the impeachment crisis, Samsung Biologics has boosted expectations for its performance from the beginning of the year by generating large-scale foreign currency sales.

A view of Samsung Biologics Plant 4 located in Songdo, Incheon. Provided by Samsung Biologics

On the 14th, Samsung Biologics announced through a public disclosure that it had signed a mega contract for contract manufacturing (CMO) worth $1.41011 billion, approximately 2.0747 trillion KRW, with a European pharmaceutical company. The contract period extends until December 31, 2030, and the client and product names have not been disclosed due to confidentiality agreements.

Accordingly, Samsung Biologics has once again broken its own record for the largest order. This comes just over three months after signing a contract worth 1.7028 trillion KRW with an Asia-based pharmaceutical company in October last year.

In terms of global market expansion, Samsung Biologics further solidified its position by consecutively signing three 'big deals' worth about 1 trillion KRW each in major global markets such as the United States, Europe, and Asia last year. The annual order amount for 2024 reached a record high of 5.4035 trillion KRW, an increase of about 1.5 times compared to the previous year.

A company representative explained, "We currently have 17 of the top 20 global pharmaceutical companies as clients," adding, "Based on overwhelming production capacity, quality competitiveness, and numerous track records, the cumulative order amount since the company's founding has surpassed $17.6 billion."

Samsung Biologics is expanding its production capacity proactively to meet the increasing demand for biopharmaceuticals. The 5th plant, scheduled to begin operations in April, is under construction as an 180,000-liter production facility that consolidates the best practices from plants 1 through 4. Once completed, Samsung Biologics will secure a total production capacity of 784,000 liters.

In terms of quality, the company has demonstrated outstanding competitiveness throughout the entire pharmaceutical manufacturing and management process, achieving a 99% batch success rate. Up to last year, it obtained a total of 340 manufacturing approvals from global regulatory agencies, including 41 from the U.S. Food and Drug Administration (FDA) and 36 from the European Medicines Agency (EMA). The number of approvals is increasing annually in line with production capacity expansion and order growth. The pass rate for regulatory inspections also remains at the industry's highest level.

Samsung Biologics is actively promoting its competitiveness and strengthening business networking and order activities by continuously participating in large-scale pharmaceutical and bio industry conferences held on the global stage in the United States, Europe, and Asia. Currently, it is participating in the '2025 J.P. Morgan Healthcare Conference (JPMHC),' the largest investment event in the pharmaceutical and bio industry, held from the 13th to the 16th (local time) in San Francisco, USA. The company is actively meeting with investors and potential clients to showcase Samsung Biologics' differentiated global contract development and manufacturing organization (CDMO) competitiveness and is focusing on strengthening networking for business expansion.